ClinicalTrials.gg
Not yet recruitingNCT07946289INTERESTUpdated Nov 18, 2026

Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive Treatment

A Phase 2 interventional study of Anakinra in Myeloproliferative Neoplasm, sponsored by University Hospital, Brest. Not yet recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Hospital, Brest · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Myeloproliferative Disorders by University Hospital, Brest — 3 open to participants now, 6 under way, none of them phase 3. Myeloproliferative Disorders · University Hospital, Brest.

Started
2027
the only one that year
Phase 2
Only one
of the 10
Registered
10th of 10
by date

Among the 10 studies in Myeloproliferative Disorders by University Hospital, Brest, this one is the only one that started in 2027, is the only one in phase 2, and was the 10th registered.

Myeloproliferative Disorders

667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

3 of the 10 studies in Myeloproliferative Disorders by University Hospital, Brest are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Myeloproliferative Disorders by University Hospital, Brest, or all of them as a file.
02

Study summary

Myeloproliferative neoplasms (MPNs) - polycythemia vera, essential thrombocythemia, and primary myelofibrosis - are characterized by excessive myeloid proliferation driven by mutations affecting the JAK2, CALR, and MPL genes, resulting in constitutive activation of hematopoietic cytokine signaling pathways. These hematological malignancies carry an increased risk of thrombosis and may evolve toward secondary myelofibrosis or acute leukemia. Bone marrow inflammation, particularly through interleukin-1 (IL-1), plays a major role in clonal expansion and the clinical expression of these diseases, as demonstrated by preclinical models showing the beneficial effect of its inhibition.

Anakinra, an IL-1 receptor antagonist widely used in rheumatology but never evaluated in MPNs, represents a promising therapeutic option. This proof-of-concept study will randomize 50 patients with a suboptimal response to cytoreductive therapy into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or cytoreductive therapy alone (n=25). The primary endpoint will be the reduction in serum calprotectin levels, a key inflammatory marker of the IL-1 loop that has recently demonstrated prognostic relevance in MPNs. Secondary endpoints will include improvements in hematological parameters, driver mutation allelic burden, pro-inflammatory cytokines, and quality of life.

This study represents an essential step toward larger trials aimed at demonstrating a durable reduction in thrombotic risk and disease progression.

Read the detailed description

Eligible patients will be identified during routine follow-up visits. After signature of informed consent and confirmation of all eligibility criteria - including a negative urine pregnancy test for women of childbearing potential - patients will be randomized into two arms: anakinra 100 mg/day administered subcutaneously in combination with ongoing cytoreductive therapy (n=25), or ongoing cytoreductive therapy alone (n=25), for a duration of 3 months.

Clinical and laboratory assessments (CBC, CRP, circulating CD34+ cells, allelic burden, calprotectin, cytokines, quality of life) will be performed at baseline, at 3 months, and at 6 months. An additional visit at 1 month is planned in the anakinra arm to assess tolerability. Patients may withdraw at any time, with reasons documented in the eCRF.

The addition of an anti-IL-1 treatment to cytoreductive therapy could improve its efficacy by promoting control of the mutated clone, which is poorly targeted by current cytoreductive agents other than interferon-α, often poorly tolerated. Better clonal control could limit phenotypic progression, reduce thrombotic risk, and improve hematological response, particularly in the megakaryocytic lineage.

The impact on myelofibrosis, observed in mice, and the improvement in quality of life through reduction of systemic inflammation remain to be confirmed in humans. Not all patients will necessarily benefit from this approach, justifying this exploratory study to evaluate its potential and feasibility.

The risks associated with anakinra are predictable and well documented (local reactions, minor systemic effects, infectious risk), mitigated by the short treatment duration and close monitoring. The benefit-risk ratio is considered favorable.

03

Conditions studied

  • Myeloproliferative Neoplasm

Keywords

  • Anakinra
  • myeloproliferative neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MPN: PV, ET, or PMF according to WHO criteria
  • Stable cytoreductive therapy for at least 6 months
  • Incomplete hematologic response according to ELN criteria, excluding bone marrow, OR complete hematologic response with anemia in ET, OR persistence of general clinical symptoms (fever, night sweats, pruritus, fatigue > 5/10 on VAS)
  • Adult patient capable of providing

Exclusion criteria

Exclusion Criteria:

  • Recurrent or poorly controlled infections
  • Thrombocytopenia \< 100 G/L
  • Neutropenia \< 1 G/L
  • to the active substance, any , or proteins derived from Escherichia coli
  • Concomitant therapy
  • Refusal to participate
  • Patient under legal protection (guardianship, curatorship, etc.)
  • Patients unable to consent.
  • Positive urine pregnancy test at screening / pregnant or breastfeeding women.
  • Lack of understanding of questionnaires or inability to follow up.
  • Women of unwilling to use a highly effective methods
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Anakinra + cytoreductive therapy

    Anakinra 100 mg/day subcutaneously for 3 months, added to ongoing standard cytoreductive therapy (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. Additional Month 1 safety/tolerability visit (clinical exam, routine biology, AE/SAE and injection-site reaction review, compliance check) and an injection diary for adherence.

    Drug: Anakinra

  • No intervention
    Cytoreductive therapy alone

    Standard cytoreductive therapy continued alone, with no additional study treatment (n=25). Assessments at baseline, Month 3 and Month 6: clinical examination, EORTC QLQ-C30 quality-of-life questionnaire, and symptom VAS (pruritus, fever, night sweats). Routine biology at each visit (CBC, biochemistry, CRP, ferritin). Research and monitoring biology at baseline/M3/M6: serum calprotectin (primary endpoint), multiplex inflammatory cytokines, driver mutation allelic burden (JAK2 V617F, CALR exon 9, MPL W515), and circulating CD34+ cells. No Month 1 visit.

Interventions

  • DrugAnakinra

    Recombinant human interleukin-1 receptor antagonist (Kineret 100 mg/0.67 mL prefilled syringe). Administered at 100 mg once daily by subcutaneous injection for 3 months, in addition to ongoing standard cytoreductive therapy. Self-injection or home-nurse administration; adherence tracked via injection diary.

06

What researchers measure

Primary outcomes

  1. Change in serum calprotectin levels

    Calprotectin levels are measured on serum samples by centralized analysis (µg/mL)

    Time frame: Baseline and Month 3

Secondary outcomes

  1. Improvement (yes/no) of the response status between baseline and month 3.

    Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

    Time frame: Month 3

  2. Improvement (yes/no) of the response status between baseline and month 6.

    Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

    Time frame: Month 6

  3. Improvement (yes/no) of the response status between month 3 and month 6.

    Improvement of the response status is defined according to international consensus criteria from the IWG-MRT/ELN 2013 (Barosi et al. / Tefferi et al., Blood 2013).

    Time frame: Month 6

  4. Hemoglobin count

    Measurement of Hemoglobin in g/dL

    Time frame: Baseline

  5. Hematocrit count

    Measurement of Hematocrit in %

    Time frame: Baseline

  6. White blood cell count

    Measurement of WBC in G/L

    Time frame: Baseline

  7. Platelet cell count

    Measurement of Platelets in G/L

    Time frame: Baseline

  8. Hemoglobin count

    Measurement of Hemoglobin in g/dL

    Time frame: Month 3

  9. Hematocrit count

    Measurement of Hematocrit in %

    Time frame: Month 3

  10. White blood cell count

    Measurement of WBC in G/L

    Time frame: Month 3

  11. Platelet cell count

    Measurement of Platelets in G/L

    Time frame: Month 3

  12. Hemoglobin count

    Measurement of Hemoglobin in g/dL

    Time frame: Month 6

  13. Hematocrit count

    Measurement of Hematocrit in %

    Time frame: Month 6

  14. White blood cell count

    Measurement of WBC in G/L

    Time frame: Month 6

  15. Platelet cell count

    Measurement of Platelets in G/L

    Time frame: Month 6

  16. Treatment-related adverse event for experimental group

    A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

    Time frame: Month 1

  17. Treatment-related adverse event for experimental group

    A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

    Time frame: Month 3

  18. Treatment-related adverse event for experimental group

    A treatment-related adverse event (yes/no) is defined as the occurrence of at least one of the following events: hepatic event, severe infection, pulmonary event, drug hypersensitivity syndrome, or injection-site reaction (maculopapular rash or urticaria).

    Time frame: Month 6

  19. Adherence to treatment regimen for experimental group

    Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between baseline and month 1. Days with missing diary entries will be excluded from the calculation.

    Time frame: Month 1

  20. Adherence to treatment regimen for experimental group

    Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 1 and month 2. Days with missing diary entries will be excluded from the calculation

    Time frame: Month 2

  21. Adherence to treatment regimen for experimental group

    Daily self-reported treatment intake (Yes/No). Treatment adherence will be measured as the percentage of days on which the treatment was taken between month 2 and month 3. Days with missing diary entries will be excluded from the calculation.

    Time frame: Month 3

  22. QLQ-C30 Summary Score

    The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

    Time frame: Baseline

  23. QLQ-C30 Summary Score

    The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

    Time frame: Month 3

  24. QLQ-C30 Summary Score

    The EORTC QLQ-C30 Summary Score will be calculated using 13 items of the EORTC QLQ-C30 questionnaire, version 3.0: physical functioning (items 1-5), role functioning (items 6-7), emotional functioning (items 21-24), cognitive functioning (items 20 and 25), social functioning (items 26-27), fatigue (items 10, 12, 18), nausea and vomiting (items 14-15), pain (items 9 and 19), dyspnoea (item 8), insomnia (item 11), appetite loss (item 13), constipation (item 16), and diarrhoea (item 17). Symptom scores are reversed before calculation. The score ranges from 0 to 100, with higher score indicating better outcome.

    Time frame: Month 6

  25. Global health status / QoL score

    Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

    Time frame: Baseline

  26. Global health status / QoL score

    Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

    Time frame: Month 3

  27. Global health status / QoL score

    Global health status / QoL score will be calculated using items 29 and 30 of EORTC QLQ-C30 questionnaire version 3.0. The score ranges from 0 to 100, with higher score indicating better health status/quality of life.

    Time frame: Month 6

  28. Patient-reported symptom severity over the previous 4 weeks for pruritus

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Baseline

  29. Patient-reported symptom severity over the previous 4 weeks for fever

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Baseline

  30. Patient-reported symptom severity over the previous 4 weeks for fever night sweats

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Baseline

  31. Patient-reported symptom severity over the previous 4 weeks for pruritus

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 3

  32. Patient-reported symptom severity over the previous 4 weeks for fever

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 3

  33. Patient-reported symptom severity over the previous 4 weeks for fever night sweats

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 3

  34. Patient-reported symptom severity over the previous 4 weeks for pruritus

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 6

  35. Patient-reported symptom severity over the previous 4 weeks for fever

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 6

  36. Patient-reported symptom severity over the previous 4 weeks for fever night sweats

    Defined as the score on a 10-point Visual Analog Scale

    Time frame: Month 6

  37. Inflammatory biological profile

    Measurement of IL-1β cytokines in pg/mL.

    Time frame: Baseline

  38. Inflammatory biological profile

    Measurement of IL-1β cytokines in pg/mL.

    Time frame: Month 3

  39. Inflammatory biological profile

    Measurement of IL-1β cytokines in pg/mL.

    Time frame: Month 6

  40. Inflammatory biological profile

    Measurement of IL-6 cytokines in pg/mL.

    Time frame: Baseline

  41. Inflammatory biological profile

    Measurement of IL-6 cytokines in pg/mL.

    Time frame: Month 3

  42. Inflammatory biological profile

    Measurement of IL-6 cytokines in pg/mL.

    Time frame: Month 6

  43. Inflammatory biological profile

    Measurement of IL-8 cytokines in pg/mL.

    Time frame: Baseline

  44. Inflammatory biological profile

    Measurement of IL-8 cytokines in pg/mL.

    Time frame: Month 3

  45. Inflammatory biological profile

    Measurement of IL-8 cytokines in pg/mL.

    Time frame: Month 6

  46. Inflammatory biological profile

    Measurement of MIP-1β cytokines in pg/mL.

    Time frame: Baseline

  47. Inflammatory biological profile

    Measurement of MIP-1β cytokines in pg/mL.

    Time frame: Month 3

  48. Inflammatory biological profile

    Measurement of MIP-1β cytokines in pg/mL.

    Time frame: Month 6

  49. Inflammatory biological profile

    Measurement of TNF-α cytokines in pg/mL.

    Time frame: Baseline

  50. Inflammatory biological profile

    Measurement of TNF-α cytokines in pg/mL.

    Time frame: Month 3

  51. Inflammatory biological profile

    Measurement of TNF-α cytokines in pg/mL.

    Time frame: Month 6

  52. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

    Time frame: Baseline

  53. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

    Time frame: Month 3

  54. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using JAK2V617F quantification.

    Time frame: Month 6

  55. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

    Time frame: Baseline

  56. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

    Time frame: Month 3

  57. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using CALR exon 9 quantification.

    Time frame: Month 6

  58. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

    Time frame: Baseline

  59. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

    Time frame: Month 3

  60. Allele burden of the driver mutation

    Variant allele frequency (VAF) of the driver mutation will be measured using MPL W515 quantification.

    Time frame: Month 6

  61. Fibrosis markers

    Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

    Time frame: Baseline

  62. Fibrosis markers

    Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

    Time frame: Month 3

  63. Fibrosis markers

    Quantification of circulating CD34+ cells by flow cytometry as a surrogate marker of bone marrow fibrosis.

    Time frame: Month 6

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Aug 2028, 18 months later.

Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's planned 18 months is below that.

Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Nov 18, 2026
StartEst.
Feb 1, 2027
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946289
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Feb 1, 2027 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Eric LIPPERT, Pr
Contact
eric.lippert@chu-brest.fr
0229247037

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion